CN102423468A - Chinese medicinal composition for resisting hepatic fibrosis and preparation method and use thereof - Google Patents
Chinese medicinal composition for resisting hepatic fibrosis and preparation method and use thereof Download PDFInfo
- Publication number
- CN102423468A CN102423468A CN2011103795986A CN201110379598A CN102423468A CN 102423468 A CN102423468 A CN 102423468A CN 2011103795986 A CN2011103795986 A CN 2011103795986A CN 201110379598 A CN201110379598 A CN 201110379598A CN 102423468 A CN102423468 A CN 102423468A
- Authority
- CN
- China
- Prior art keywords
- hepatic fibrosis
- chinese medicinal
- chinese medicine
- medicine composition
- medicinal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal composition for resisting hepatic fibrosis and a preparation method and use thereof. The Chinese medicinal composition is prepared from the following Chinese medicinal materials: herb of virgate vormwood, white atractylodes rhizome, prepared aconite root, dried ginger, honey-fried licorice root and cinnamon, according to the mass ratio of 3:6:1.5:1.5:3:1. The Chinese medicinal composition is prepared through subjecting the Chinese medicinal materials, i.e. the herb of virgate vormwood, the white atractylodes rhizome, the prepared aconite root, the dried ginger, the honey-fried licorice root and the cinnamon to water decoction according to a matching ratio, extracting and concentrating. Proved by the pharmacodynamic tests, the Chinese medicinal composition disclosed by the invention can lower the serum transaminase of hepatic fibrosis model mice, can relieve the degree of the liver collagen deposition of the hepatic fibrosis model mice, can improve the hepatic inflammation and the fibrosis pathological change of the hepatic fibrosis model mice, and has the effect of resisting the pathological change of the hepatic fibrosis, so that the Chinese medicinal composition can be used for preparing a pharmaceutical preparation for resisting the hepatic fibrosis.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition of anti-hepatic fibrosis, belong to technical field of Chinese medicines.
Background technology
Hepatic fibrosis is the common pathologic basis that various chronic hepatopathys are developed to liver cirrhosis, its essence is that liver inner cell epimatrix is synthetic unbalance with degraded, cause extracellular matrix especially collagen deposit in a large number at liver.The hepatic fibrosis sustainable development causes the corresponding organ dysfunction with depleted, the serious harm life and health.Slow down, stop even reverse hepatic fibrosis, to the generation that reduces severe complication, improve patient's quality of life and improve survival rate and be significant.Therefore, the medicine of development anti-hepatic fibrosis has tangible using value.
Hepatic fibrosis is a dynamic pathological process, a plurality of stages that comprise generation, develop and disappear, and each stage has a plurality of links to influence each other, therefore, only not ideal enough to the effect of single link treatment hepatic fibrosis.The Chinese medicine compound composition is various, has multipath, too many levels, multi-level comprehensive effect, and is evident in efficacy to the hepatic fibrosis that pathological changes is complicated, and has broad application prospects.
Summary of the invention
One of technical problem to be solved by this invention provides a kind of Chinese medicine composition of anti-hepatic fibrosis, and two of technical problem to be solved provides the method for preparing and the application of described Chinese medicine composition.
In order to solve the problems of the technologies described above, the technical scheme that the present invention adopts is following:
A kind of Chinese medicine composition of anti-hepatic fibrosis is characterized in that, is raw material by Chinese crude drug Herba Artemisiae Scopariae, the Rhizoma Atractylodis Macrocephalae, Radix Aconiti Lateralis Preparata, Rhizoma Zingiberis, Radix Glycyrrhizae Preparata, Cortex Cinnamomi, is 3: 6: 1.5 by mass ratio: be prepared from 1.5: 3: 1.
A kind of method for preparing of Chinese medicine composition of described anti-hepatic fibrosis is to take by weighing Chinese crude drug Herba Artemisiae Scopariae, the Rhizoma Atractylodis Macrocephalae, Radix Aconiti Lateralis Preparata, Rhizoma Zingiberis, Radix Glycyrrhizae Preparata and Cortex Cinnamomi at first in proportion, and wherein Cortex Cinnamomi is removed the peel; Water decocts 2 times together then, and from each 1 hour of the timing of seething with excitement, decoction use first time quality is 10 times of total quality of medicinal material, and the quality of decoction use for the second time is 8 times of total quality of medicinal material; Merge decoction liquor at last twice, concentrated being prepared from.
The pharmaceutical preparation that Chinese medicine composition of the present invention or described Chinese medicine composition and pharmaceutically acceptable pharmaceutical carrier can be applicable to prepare anti-hepatic fibrosis.
Described pharmaceutical preparation can be any pharmaceutically useful dosage form, and these dosage forms comprise: tablet, sugar coated tablet, film coated tablet, enteric coated tablet, capsule, hard capsule, soft capsule, oral liquid, suck agent, granule, electuary, pill, powder, unguentum, sublimed preparation, suspensoid, powder, solution, injection, suppository, ointment, plaster, cream, spray, drop, patch; The preferred oral dosage form, as: capsule, tablet, oral liquid, granule, pill, powder, sublimed preparation, unguentum etc.Described peroral dosage form can contain excipient commonly used, such as binding agent, filler, diluent, tablet agent, lubricant, disintegrating agent, coloring agent, flavoring agent and wetting agent, can carry out coating to tablet in case of necessity.Suitable filler comprises cellulose, mannitol, lactose and other similar filler; Suitable disintegrating agent comprises starch, polyvinylpyrrolidone and starch derivatives, for example sodium starch glycollate; Suitable lubricant comprises, for example magnesium stearate; The acceptable wetting agent of appropriate drug comprises sodium lauryl sulphate.
Chinese medicine composition of the present invention is made up of Herba Artemisiae Scopariae, the Rhizoma Atractylodis Macrocephalae, Radix Aconiti Lateralis Preparata, Rhizoma Zingiberis, Radix Glycyrrhizae Preparata, Cortex Cinnamomi.Herba Artemisiae Scopariae, Radix Aconiti Lateralis Preparata and Cortex Cinnamomi are share in the side, using medicines of both cold and hot natures simultaneously, warming YANG jaundice eliminating; Rhizoma Zingiberis, the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae spleen invigorating warming middle-JIAO for eliminating dampness, full side cures mainly the YIN jaundice coldness of the body, deep-thready pulse, body such as dark yellow, normal urination person.
The present invention adopts carbon tetrachloride (carbon tetrachloride, the CCl of extensive use
4) inductive hepatic fibrosis in mice model; Use Chinese medicine composition 6g crude drug of the present invention/kg gastric infusion; The result shows that Chinese medicine composition of the present invention has the transaminase lowering activity to the Liver Fibrosis Model mice, can alleviate liver collagen deposition degree; Improve liver inflammatory and fibrosis pathology and change effect with anti-hepatic fibrosis pathological changes.
Description of drawings
Fig. 1 is that Chinese medicine composition of the present invention is to CCl
4The influence of the serum aminotransferase activity of Liver Fibrosis Model mice.
Fig. 2 is that Chinese medicine composition of the present invention is to CCl
4The influence of the hepatic tissue hydroxyproline of Liver Fibrosis Model mice.
Fig. 3 is that Chinese medicine composition of the present invention is to CCl
4The influence that the hepatic pathology of Liver Fibrosis Model mice changes.
Fig. 4 is that Chinese medicine composition of the present invention is to CCl
4The influence of the liver collagen deposition of Liver Fibrosis Model mice.
Among the figure: N-representes normal group; M-representation model matched group; Y representes Herba Artemisiae Scopariae Atracty-lodis Macrocephalae and Aconiti Praeparatae Decoction group; P-representes positive controls.
The specific embodiment
Below in conjunction with specific embodiment and accompanying drawing, further set forth the present invention.These embodiment are interpreted as only being used to explain the present invention rather than being used to limit protection scope of the present invention.After the content of having read the present invention's record, those skilled in the art can do various changes or modification to the present invention, and these equivalences change and modify and fall into claims of the present invention institute restricted portion equally.
Embodiment
Get Chinese crude drug Herba Artemisiae Scopariae 300 grams, the Rhizoma Atractylodis Macrocephalae 600 grams, Radix Aconiti Lateralis Preparata 150 grams, Rhizoma Zingiberis 150 grams, Radix Glycyrrhizae Preparata 300 grams and Cortex Cinnamomi (peeling) 100 grams; Decocting boils 2 times; From each 1 hour of timing of boiling, decoct for the first time and uses quality to be 16kg (for 10 times of total quality of medicinal material), decoct for the second time and use quality to be 12.8kg (be total quality of medicinal material 8 times); Merge decoction liquor twice, simmer down to 2000mL concentrated solution.
Test Example (anti-CCl
4The hepatic fibrosis mouse experiment)
Select male C57BL/6 mice in 10 ages in week for use, the cleaning level is supplied with by Shanghai Slac Experimental Animal Co., Ltd..Mice is divided into normal group (N), model group (M), Herba Artemisiae Scopariae Atracty-lodis Macrocephalae and Aconiti Praeparatae Decoction group (Y) and positive drug group (P) at random.Except that normal group (lumbar injection equivalent normal saline), all the other each groups are all with 10%CCl
4Olive oil solution 2ml/kg mice body weight lumbar injection is injected continuous 4 weeks weekly 3 times.
From modeling, Herba Artemisiae Scopariae Atracty-lodis Macrocephalae and Aconiti Praeparatae Decoction group gives Chinese medicine composition 6g crude drug of the present invention/kg body weight and irritates stomach, and the positive drug group gives N-acetyl-L-cysteine 0.15g/kg body weight and irritates stomach, and in totally 4 weeks, normal group and model group wait the capacity normal saline.Medication finishes the back and measures mice serum glutamate pyruvate transaminase, glutamic oxaloacetic transaminase, GOT activity and hepatic tissue hydroxyprolin levels, carries out hepatic tissue pathology dyeing and the inspection of Sirius red colouring.
Table 1 Chinese medicine composition of the present invention is to CCl
4Hepatic fibrosis mice ALT, the active influence of AST
| Group | n | ALT active (IU/L) | AST active (IU/L) |
| N | 10 | 106.14±31.72 ** | 145.11±42.34 ** |
| M | 10 | 191.72±44.24 | 232.55±58.11 |
| Y | 10 | 138.51±39.42 * | 159.74±42.37 ** |
| P | 10 | 169.30±51.41 | 189.82±66.70 |
Annotate: compare with model group,
*P＜0.05,
*P＜0.01.
Result of the test shows: Chinese medicine composition of the present invention can reduce the mice serum glutamate pyruvate transaminase and glutamic oxaloacetic transaminase, GOT active (seeing that table 1 is with shown in Figure 1), among the figure:
*P＜0.05,
*P＜0.01vs model.Chinese medicine composition of the present invention also can reduce mouse liver hydroxyproline content (see figure 2).Hepatic tissue HE coloration result shows, the visible portal area of model group massive inflammatory cells infiltrated, a large amount of hypertrophy of fibroblast, extensive degeneration of hepatocyte and necrosis; Inflammatory cell infiltration and fibroblast proliferation obviously reduce after the Chinese medicine composition medication of the present invention, and hepatocellular degeneration and necrosis alleviate (see figure 3); Hepatic tissue Sirius is red collagen staining result show, the visible more pseudolobuli in model group portal area forms, a large amount of collagen fiber depositions; Chinese medicine composition group of the present invention does not see that pseudolobuli forms, and the collagen fiber deposition alleviates (see figure 4).
To sum up experimental result shows: Chinese medicine composition of the present invention has the effect of anti-hepatic fibrosis pathological changes.
Claims (3)
1. the Chinese medicine composition of an anti-hepatic fibrosis, it is characterized in that: by Chinese crude drug Herba Artemisiae Scopariae, the Rhizoma Atractylodis Macrocephalae, Radix Aconiti Lateralis Preparata, Rhizoma Zingiberis, Radix Glycyrrhizae Preparata, Cortex Cinnamomi is raw material, by mass ratio 3: 6: 1.5: be prepared from 1.5: 3: 1.
2. the method for preparing of the Chinese medicine composition of the described anti-hepatic fibrosis of claim 1, it is characterized in that: take by weighing Chinese crude drug Herba Artemisiae Scopariae, the Rhizoma Atractylodis Macrocephalae, Radix Aconiti Lateralis Preparata, Rhizoma Zingiberis, Radix Glycyrrhizae Preparata and Cortex Cinnamomi at first in proportion, wherein Cortex Cinnamomi is removed the peel; Water decocts 2 times together then, and from each 1 hour of the timing of seething with excitement, decoction use first time quality is 10 times of total quality of medicinal material, and the quality of decoction use for the second time is 8 times of total quality of medicinal material; Merge decoction liquor at last twice, concentrated being prepared from.
3. described Chinese medicine composition of claim 1 or described Chinese medicine composition and the pharmaceutically acceptable pharmaceutical carrier application in the pharmaceutical preparation of preparation anti-hepatic fibrosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110379598 CN102423468B (en) | 2011-11-24 | 2011-11-24 | Chinese medicinal composition for resisting hepatic fibrosis and preparation method and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110379598 CN102423468B (en) | 2011-11-24 | 2011-11-24 | Chinese medicinal composition for resisting hepatic fibrosis and preparation method and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102423468A true CN102423468A (en) | 2012-04-25 |
| CN102423468B CN102423468B (en) | 2013-06-19 |
Family
ID=45957552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110379598 Active CN102423468B (en) | 2011-11-24 | 2011-11-24 | Chinese medicinal composition for resisting hepatic fibrosis and preparation method and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102423468B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111150826A (en) * | 2020-02-17 | 2020-05-15 | 河南中医药大学 | Traditional Chinese medicine for treating post-compensation hepatitis B cirrhosis |
| CN112891545A (en) * | 2021-03-12 | 2021-06-04 | 中国药科大学 | Anti-hepatic fibrosis composition and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101607011A (en) * | 2009-07-24 | 2009-12-23 | 崔延昌 | A kind of Chinese medicine medicine for the treatment of cholecystitis post-operative complacation |
| CN101693094A (en) * | 2009-09-07 | 2010-04-14 | 湖南康普制药有限公司 | Traditional Chinese medicine compound preparation for treating viral hepatitis and complication |
-
2011
- 2011-11-24 CN CN 201110379598 patent/CN102423468B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101607011A (en) * | 2009-07-24 | 2009-12-23 | 崔延昌 | A kind of Chinese medicine medicine for the treatment of cholecystitis post-operative complacation |
| CN101693094A (en) * | 2009-09-07 | 2010-04-14 | 湖南康普制药有限公司 | Traditional Chinese medicine compound preparation for treating viral hepatitis and complication |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111150826A (en) * | 2020-02-17 | 2020-05-15 | 河南中医药大学 | Traditional Chinese medicine for treating post-compensation hepatitis B cirrhosis |
| CN112891545A (en) * | 2021-03-12 | 2021-06-04 | 中国药科大学 | Anti-hepatic fibrosis composition and application thereof |
| CN112891545B (en) * | 2021-03-12 | 2022-06-07 | 中国药科大学 | Anti-hepatic fibrosis composition and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102423468B (en) | 2013-06-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102397372A (en) | Medicinal composition and pharmaceutical preparation and application thereof to treating irritable bowel syndrome | |
| CN102423468B (en) | Chinese medicinal composition for resisting hepatic fibrosis and preparation method and use thereof | |
| CN102302544B (en) | Chinese medicinal composition for preventing and treating hepatic fibrosis | |
| CN102429977B (en) | Medicine for treating diabetes | |
| CN103223069A (en) | Traditional Chinese medicine composition for treating hepatitis | |
| CN100364601C (en) | Chinese traditional medicine composition for treating diabetic nephropathy | |
| CN104043045A (en) | Pharmaceutical composition for treating optic atrophy | |
| CN101036708A (en) | Medicine composition for treatment of cardio-cerebralvascular disease | |
| CN103285343B (en) | Medicine for treating liver cancer and preparation method thereof | |
| CN102716436B (en) | Capsule for treating atrophic gastritis | |
| CN103239674B (en) | Antineoplastic traditional Chinese medicine composition and preparation method thereof | |
| CN103041320B (en) | Traditional Chinese medicine composition for treating cervical spondylosis and preparation method thereof | |
| CN104547800A (en) | Use of traditional Chinese medicine preparation in preparation of medicine for treating alcoholic fatty liver | |
| CN104000871A (en) | Drug for treating myocardial ischemia | |
| CN105902897A (en) | Pharmaceutical preparation for treating pancreatic cancer and application thereof | |
| CN104001026A (en) | Medicine for treating myocardial ischemia | |
| CN106420901B (en) | A kind of herbal mixture for treating fatty liver | |
| CN104587281A (en) | Spleen invigoration and diuresis promoting traditional Chinese medicine composition for treating cirrhosis and preparation | |
| CN104784472A (en) | Traditional Chinese medicine composition for decreasing blood sugar to treat diabetes | |
| CN102357171A (en) | Traditional Chinese medicine composition for preventing and curing hepatic fibrosis, and preparation method and application thereof | |
| CN102631430B (en) | Traditional Chinese medicine composition for resisting hepatic fibrosis, as well as preparation method and application thereof | |
| CN103705868B (en) | One treats hyperthyroid pharmaceutical composition and application thereof | |
| CN108295221B (en) | Traditional Chinese medicine composition for treating Parkinson's disease and preparation method and application thereof | |
| CN110496181B (en) | Chinese medicinal capsule and its preparation method | |
| CN105213774A (en) | A kind of pharmaceutical composition for the treatment of chronic heart failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |